Cyrus L. Harmon, Ph.D.
Chief Executive Officer, President and Co-Founder
Cyrus is the founding CEO and President of Olema. He was the co-founder and CEO of Neomorphic, Inc., a computational biology company that was acquired by Affymetrix, Inc., where he served as Vice President, Computational Genomics and General Manager. He received a Ph.D. in Molecular and Cell Biology from UC Berkeley, where he applied computer vision and machine learning techniques to the analysis of spatial patterns of gene expression in Drosophila melanogaster.
Peter J. Kushner, Ph.D.
Chairman, Chief Scientific Officer and Co-Founder
Peter is the founding Chairman and CSO of Olema. He is an Emeritus Professor in the Department of Medicine, Division of Endocrinology, University of California, San Francisco. He has studied the mechanisms and functions of the estrogen receptors and has published some of the most highly cited papers in the field, including ones showing the molecular mechanism of action of the breast cancer drug tamoxifen. Along with other colleagues from UCSF he was a founder of Serra Pharmaceuticals, a California biotechnology company which was purchased by KaroBio AB, in Stockholm, Sweden. He served on the Board of Directors of KaroBio from 1996 to 2002.
David C. Myles, Ph.D.
Executive Vice President, Drug Development
David is an experienced biotechnology executive, having served in management roles at Epiphany Biosciences, Kosan Biosciences, and Chiron Corporation. He has directed research programs in cancer, infectious disease, and metabolic disease, among other areas. Prior entering the biotechnology business, he was an Assistant Professor in the Department of Chemistry and Biochemistry at UCLA where his laboratory developed new methods for the preparation of biologically active natural products and analogs. David obtained his Ph.D. from Yale University and was an NIH post-doctoral fellow at Harvard University.
Leslie Hodges-Gallagher, Ph.D.
Vice President, Molecular Biology Research
Leslie's research investigates biochemical strategies to improve the efficacy of anti-hormonal therapies for breast cancer and other hormone-related conditions. She was a postdoctoral researcher at the University of California San Francisco in the Department of Medicine under Dr. Peter Kushner. She received her Ph.D. from the University of Texas Graduate School of Biomedical Sciences in the program of Environmental and Molecular Carcinogenesis where her research focused on identifying biomarkers of agonist activity in breast and uterine cells.
Richard received a B.A. in Biochemistry and Molecular Biology from the University of California, Santa Cruz and subsequently worked in dermatology medical research at UCSF/SFVAMC. At Olema he works on translational projects to expand treatment options for cancer patients. In his free time, he enjoys exercising and reading. Grateful to be working on impactful projects, Richard is focused on his work to improve the quality life of cancer patients.